Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

45 results about "Tricyclic antidepressant" patented technology

Tricyclic antidepressants (TCAs) are a class of medications that are used primarily as antidepressants. TCAs were discovered in the early 1950s and were marketed later in the decade. They are named after their chemical structure, which contains three rings of atoms. Tetracyclic antidepressants (TeCAs), which contain four rings of atoms, are a closely related group of antidepressant compounds.

Combinations for the treatment of inflammatory disorders

The invention features a method for treating a patient having an inflammatory disorder, by administering to the patient (i) a tricyclic antidepressant (e.g., amoxapine); and (ii) a corticosteroid (e.g., prednisolone) simultaneously or within 14 days of each other in amounts sufficient to reduce or inhibit inflammation.
Owner:ZALICUS INC

Compounded transdermal pain management

The present embodiments relate to topically delivered medication (compounded) for treatment of pain, inflammation, muscle fatigue, spasms, and / or other ailments. A transdermal cream may provide the effective topical administration of multiple medications simultaneously. The transdermal cream may include a salt load of approximately 30% or greater. The transdermal cream may include a unique base composition such that the transdermal cream may be able to remain stable and avoid degradation for six months or more and capable of effective delivery of active ingredient concentrations exceeding approximately 40% or more of the total formulation weight. The active ingredients may include a nerve depressant, NSAID, muscle relaxant, opiate agonist, local anesthetic, NMDA receptor antagonist, and a tricyclic antidepressant. In one embodiment, the transdermal cream may comprise ketamine HCL, gabapentin, clonidine HCL and baclofen. The transdermal cream may deliver an enhanced topical delivery flux of ketamine via a single transdermal application.
Owner:CMPD LICENSING

Methods and compositions for treatment of nicotine dependence and dementias

In accordance with the present invention, it has been unexpectedly found that the administration of an acetylcholinesterase inhibitor in combination with a tricyclic antidepressant having anti-muscarinic properties provides a highly effective and well tolerated treatment for nicotine dependence and dementias, such as Alzheimer's disease (AD). In one aspect, it is effective in the treatment of nicotine dependence, as well as in the treatment and mitigation of nicotine withdrawal symptoms and in the effectuation of smoking cessation. In another aspect, it is effect in the treatment and mitigation of dementias such as Alzheimer's disease.
Owner:NEUROCURE

Lipid Emulsions in the Treatment of Systemic Poisoning

The present invention provides lipid emulsions and methods of intravenously administering lipid emulsions to treat systemic toxicity caused by foreign lipophilic and amphiphilic substances. In particular, methods are provided to treat cardiovascular impairment, such as cardiotoxicity, asystole and ischemia of the brain and heart, and neurological impairments, such as seizures and comas, caused by foreign lipophilic and amphiphilic substances, including cardiovascular impairment caused by local anesthetics, tricyclic antidepressants, sodium channel blockers, and calcium channel blockers.
Owner:RESQ PHARMA INC

Fast food safety homogeneous immunological detection reagent

The invention relates to the field of biotechnology, in particular to a homogeneous immunological detection reagent. The invention adopts a method utilizing the homogeneous enzyme multiplied immunoreaction to detect the residual amounts of harmful substances in the body fluid of animal and the extract liquor of tissue, thus harmful substance residues containing common organic small-molecule medicines and illegal medicines, such as clenbuterol hydrochloride, ractopamine, melamine, malachite green, benzodiazepines, tricyclic antidepressants and various antibiotic medicines can be detected and the invention has extremely wide application prospect and social meaning. The product developed by the invention has high sensitivity and can detect hundreds of compounds and metabolic products at the same time; and the detection is fast and accurate; and the detection data can be processed and printed automatically and can also be connected with the Internet so as to realize synchronous monitoring.
Owner:CHANGZHOU SEO BIOTECH

Medicinal compositions

The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.
Owner:KYOWA HAKKO KIRIN CO LTD

Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome

A method and a medicine for treating a human having a gastrointestinal disorder that includes irritable bowel syndrome are provided. The method includes administering a dose of the medicine to the human. The medicine includes a tricyclic antidepressant and a stool softener.
Owner:SIR ISAAC NEWTON ENTERPRISES

Treatment of Disorders and Diseases of the Colon

A method and a composition for the treatment of an Inflammatory Bowel Disease (IBD) or intestine polyposes is described. The method includes the local administration to the colon of a therapeutically effective amount of at least one Selective Serotonin Reuptake Inhibitor (SSRI) or at least one tricyclic antidepressant (TCA).
Owner:RAMOT AT TEL AVIV UNIV LTD +1

Metal cyano bonded phases

A composition for use in chromatography is provided comprising a substrate modified with a metal-cyano bonded phase. This novel cyano bonded phase provides superior performance in high performance liquid chromatography (HPLC) and provides superior selectivity, improved peak shape for basic analytes, and the ability of provide rapid separation with outstanding resolution. The composition exhibits improved storage stability, and is chemically stable over a range of pH from 1.5 to 7.5 mobile phase conditions and for more than 2000 multiple injections. A baseline separation of eight tricyclic antidepressants was achieved in less than four minutes using an isocratic mobile phase with the metal-cyano bonded phase of the present invention, compared to the long retention times and poor separation observed for traditional cyano bonded phase. The composition of this invention is particularly useful in a wide variety of chromatographic applications.
Owner:AGILENT TECH INC

Composition comprising nor-adrenaline and a net inhibitor for administering to a brain-dead, heart-beating potential organ donor

A composition, an infusion solution, a method for treatment, and a kit for intravascular administration for treatment of a brain-dead, heart-beating, respirated, potential organ donor. The composition has a non-adrenaline and NET inhibitor for noradrenaline. The NET inhibitor may be cocaine or an analogue thereof or a tricyclic antidepressant. The composition may in addition include adrenaline, hydrocortisone, thyroxin, insulin, triiodotyronine, dopamine, a vasopressor agent, such as desmopressin, and methylprednisolone. The ratio between the NET inhibitor and nor-adrenaline is about 1:1. The composition may be dissolved in pure water, Ringer's acetate solution or physiological sodium chloride solution. The composition is infused in such an amount as to maintain a mean arterial pressure of about 60 mmHg. The composition may be infused by a pump at a rate of about 1.7 ml / hour decreasing dose-dependent to about 0.4 ml / hour after 24 hours.
Owner:XVIVO PERFUSION

A pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines

Pharmaceutical compositions are disclosed for the treatment of acute, chronic and / or neuropathic pain. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an analgesic agent and a pharmaceutically acceptable carrier. The analgesic agent is selected from opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents, anti-convulsants, anti-hypertensives, anti-arrythmics, antihistamines, steroids, caffeine, and botulinum toxin. The method of using these compounds and a method of treating acute, chronic and / or neuropathic pain and migraine in a mammal including a human is also disclosed.
Owner:PFIZER PRODS ETAT DE CONNECTICUT

Method of reducing neuronal cell damage

InactiveCN101516194AImmediate or extended release formulationsBiocideSenses disorderTricyclic antidepressantPharmaceutical care
The present invention is directed to a method of reducing the occurrence of neuronal cell damage, including death, caused by transient cerebral hypoxia and / or ischemia. The method comprises the steps of: diagnosing a subject having a transient cerebral hypoxic and / or ischemic condition; and within 16 hours after onset of the condition, administering to the subject a neuroprotective amount of a pharmaceutical agent. The pharmaceutical agent is preferably selected from the group consisting of: a central nervous system stimulant (CNSS), monoamine neurotransmitter, monoamine oxidase inhibitor (MAOI), tricyclic antidepressant (TCA), or a combination thereof. Preferred agents include amphetamines, methamphetamine, methylphenidate, methylenedioxymethamphetamine, or a combination thereof.
Owner:UNIVERSITY OF MONTANA

Compounds for the treatment of ocular dryness caused by photorefractive surgery

The blocking agents of the electrical activity of the damaged nerve endings of the neuroma can be used for the treatment of dryness of the ocular surface caused by photorefractive surgery, such as excimer laser photorefractive keratectomy or laser-assisted in situ keratomileusis. The administration of said blocking agents, which include antiepileptics, anticonvulsants, anti-arrhythmic drugs, tricyclic antidepressants and local anaesthetics and, in particular, include lidocaine, tocainide, phenyloin, carbamazepine, lamotrigine, mexiletine and pregabalin, effectively reduce the sensations of ocular dryness.
Owner:UNIV MIGUEL HERNANDEZ DE ELCHE

Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith

Provides herein are compositions for the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith, comprising an estrogen, optionally estriol, and a tricyclic antidepressant, optionally amitriptyline, formulated for topical, transdermal or transmucosal administration. Also provided are methods for the production of said compositions and to uses thereof in the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith.
Owner:T&A PHARMA PTY LTD

Medicine for treating gastrointestinal disorder including fecal incontinence

InactiveUS20060148785A1Reduce and eliminate fecal incontinence and fecalReduce and eliminate fecal and fecal urgencyBiocideAnimal repellantsTricyclic antidepressantDisease
A method and a medicine for treating a human having a gastrointestinal disorder that includes fecal incontinence are provided. The method includes administering a dose of the medicine to the human. The medicine includes a tricyclic antidepressant and a stool softener.
Owner:LUNDEEN JAMES E

Medicine for treating gastrointestinal disorder in a non-human mammal

InactiveUS20060148784A1Reduce and eliminate fecal incontinenceSoftenBiocideAnimal repellantsDiseaseTricyclic antidepressant
A method and a medicine for treating a non-human mammal having a gastrointestinal disorder that includes fecal incontinence and / or irritable bowel syndrome are provided. The method includes administering a dose of the medicine to the mammal. The medicine includes a tricyclic antidepressant and a stool softener.
Owner:LUNDEEN JAMES E

Method for the treatment of urinary incontinence

Urinary incontinence is alleviated in a mammal by administering to the mammal a urinary incontinence alleviating amount of dextromethorphan, dextrorphan, their mixtures and / or pharmaceutically acceptable salts, alone or in combination with a pharmacologically active agent such as an anticholinergic, sympathomimetic, tricyclic antidepressant, antispasmodic, direct-acting smooth muscle relaxant, estrogen, compound having estrogen-like activity, or any combination of the foregoing.
Owner:ENDO PHARMA INC

Method and compositions for treatment of painful disorders

Chronic pain is treated with a combination of a standard dose of a non-narcotic analgesic and a low dose of a tricyclic antidepressant compound. The invention is effective in the treatment of chronic pain associated with neuropathic or fibromuscular disorders, where such pain has been unresponsive to non-narcotic analgesics alone.
Owner:WINSTON LAB

Method and medicine for treating gastrointestinal disorder including fecal incontinence

InactiveUS20060148783A1Reduce and eliminate fecal incontinence and fecalReduce and eliminate fecal and fecal urgencyBiocideAnimal repellantsTricyclic antidepressantDisease
A method and a medicine for treating a human having a gastrointestinal disorder that includes fecal incontinence are provided. The method includes administering a dose of the medicine to the human. The medicine includes a tricyclic antidepressant and a stool softener.
Owner:SIR ISAAC NEWTON ENTERPRISES

Dropping pills containing Isocarboxazid and method for preparing the same

The invention provides an isocarboxazid dripping pill and a process for preparation. The invention overcomes the shortcomings of the prior dripping pills that pure natural degrees of findings which are used by the prior dripping pills are not high, and chemosynthesis findings which are commonly used are not in food additives catalogs of some countries, and tastes of the dripping pills are worse. The invention is a pharmaceutical preparation whose natural degree is higher, safety is stronger, and side effect is lower. The medicament is mainly used to depressive patients who are resistant to tricyclic antidepressants. The invention is effective on depression with anxiety and hysteria.
Owner:TIANJIN TASLY PHARMA CO LTD

Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith

Provides herein are compositions for the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith, comprising an estrogen, optionally estriol, and a tricyclic antidepressant, optionally amitriptyline, formulated for topical, transdermal or transmucosal administration. Also provided are methods for the production of said compositions and to uses thereof in the treatment of chronic vulval or perineal pain, and of symptoms or conditions associated therewith.
Owner:T&A PHARMA PTY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products